ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

12.12.2022 - - Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML- No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax - ALX Oncology ... Seite 1

Related Keywords

United States ,American ,Harry Erba ,American Society Of Hematology ,Division Of Hematologic Malignancies ,Leukemia Program ,Oncology Holdings Inc ,Cellular Therapy At Duke University ,Holdings Inc ,American Society ,Annual Meeting ,Hematologic Malignancies ,Cellular Therapy ,Duke University ,